Comments
Loading...

Bicycle Therapeutics Analyst Ratings

BCYCNASDAQ
Logo brought to you by Benzinga Data
$8.05
-0.46-5.41%
At close: -
$8.05
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$60.00
Lowest Price Target1
$14.00
Consensus Price Target1
$33.87

Bicycle Therapeutics Analyst Ratings and Price Targets | NASDAQ:BCYC | Benzinga

Bicycle Therapeutics PLC has a consensus price target of $33.87 based on the ratings of 17 analysts. The high is $60 issued by Canaccord Genuity on February 21, 2024. The low is $14 issued by B. Riley Securities on May 2, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, RBC Capital, and B. Riley Securities on May 6, 2025, May 2, 2025, and May 2, 2025, respectively. With an average price target of $21 between Morgan Stanley, RBC Capital, and B. Riley Securities, there's an implied 160.87% upside for Bicycle Therapeutics PLC from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Feb
1
Mar
1
Apr
3
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Morgan Stanley
RBC Capital
B. Riley Securities
JMP Securities
Needham

1calculated from analyst ratings

Analyst Ratings for Bicycle Therapeutics

Buy NowGet Alert
05/06/2025Buy Now111.18%Morgan Stanley
Jeffrey Hung50%
$15 → $17MaintainsEqual-WeightGet Alert
05/02/2025Buy Now297.52%RBC Capital
Gregory Renza49%
$35 → $32MaintainsOutperformGet Alert
05/02/2025Buy Now73.91%B. Riley Securities
Kalpit Patel40%
$17 → $14MaintainsNeutralGet Alert
05/02/2025Buy Now173.29%JMP Securities
Reni Benjamin47%
$26 → $22MaintainsMarket OutperformGet Alert
05/02/2025Buy Now260.25%Needham
Ami Fadia56%
$29 → $29ReiteratesBuy → BuyGet Alert
05/01/2025Buy Now86.34%Barclays
Peter Lawson42%
$40 → $15MaintainsOverweightGet Alert
04/09/2025Buy Now272.67%Needham
Ami Fadia56%
$30 → $30ReiteratesBuy → BuyGet Alert
03/11/2025Buy Now272.67%Needham
Ami Fadia56%
$30 → $30ReiteratesBuy → BuyGet Alert
02/26/2025Buy Now222.98%Citizens Capital Markets
Reni Benjamin47%
$26 → $26ReiteratesMarket Outperform → Market OutperformGet Alert
02/26/2025Buy Now309.94%HC Wainwright & Co.
Swayampakula Ramakanth50%
$33 → $33ReiteratesBuy → BuyGet Alert
02/26/2025Buy Now272.67%Needham
Ami Fadia56%
$30 → $30ReiteratesBuy → BuyGet Alert
01/22/2025Buy Now86.34%Stephens & Co.
Sudan Loganathan32%
$15 → $15ReiteratesEqual-Weight → Equal-WeightGet Alert
01/13/2025Buy Now309.94%HC Wainwright & Co.
Swayampakula Ramakanth50%
$33 → $33ReiteratesBuy → BuyGet Alert
01/13/2025Buy Now297.52%Needham
Ami Fadia56%
$32 → $32ReiteratesBuy → BuyGet Alert
12/18/2024Buy Now222.98%JMP Securities
Reni Benjamin47%
$32 → $26MaintainsMarket OutperformGet Alert
12/16/2024Buy Now309.94%HC Wainwright & Co.
Swayampakula Ramakanth50%
$55 → $33MaintainsBuyGet Alert
12/13/2024Buy Now111.18%B. Riley Securities
Kalpit Patel40%
$28 → $17MaintainsNeutralGet Alert
11/08/2024Buy Now210.56%Stephens & Co.
Sudan Loganathan32%
→ $25Initiates → Equal-WeightGet Alert
11/01/2024Buy Now334.78%RBC Capital
Gregory Renza49%
$35 → $35ReiteratesOutperform → OutperformGet Alert
11/01/2024Buy Now583.23%HC Wainwright & Co.
Swayampakula Ramakanth50%
$55 → $55ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now372.05%Needham
Ami Fadia56%
$38 → $38ReiteratesBuy → BuyGet Alert
10/24/2024Buy Now583.23%HC Wainwright & Co.
Swayampakula Ramakanth50%
$55 → $55ReiteratesBuy → BuyGet Alert
10/24/2024Buy Now372.05%Needham
Ami Fadia56%
$38 → $38ReiteratesBuy → BuyGet Alert
09/16/2024Buy Now297.52%JMP Securities
Reni Benjamin47%
$32 → $32ReiteratesMarket Outperform → Market OutperformGet Alert
09/16/2024Buy Now583.23%HC Wainwright & Co.
Swayampakula Ramakanth50%
$55 → $55ReiteratesBuy → BuyGet Alert
09/16/2024Buy Now372.05%Needham
Ami Fadia56%
$38 → $38ReiteratesBuy → BuyGet Alert
09/09/2024Buy Now372.05%Needham
Ami Fadia56%
$38 → $38ReiteratesBuy → BuyGet Alert
09/09/2024Buy NowCantor Fitzgerald
Li Watsek40%
Reiterates → OverweightGet Alert
09/06/2024Buy Now334.78%RBC Capital
Gregory Renza49%
→ $35Initiates → OutperformGet Alert
08/07/2024Buy Now583.23%HC Wainwright & Co.
Swayampakula Ramakanth50%
$55 → $55ReiteratesBuy → BuyGet Alert
08/07/2024Buy Now496.27%Oppenheimer
Jay Olson60%
$48 → $48MaintainsOutperformGet Alert
08/07/2024Buy Now372.05%Needham
Ami Fadia56%
$38 → $38ReiteratesBuy → BuyGet Alert
08/07/2024Buy Now247.83%B. Riley Securities
Kalpit Patel40%
$33 → $28DowngradeBuy → NeutralGet Alert
05/03/2024Buy Now583.23%HC Wainwright & Co.
Swayampakula Ramakanth50%
$55 → $55ReiteratesBuy → BuyGet Alert
04/10/2024Buy Now434.16%Needham
Ami Fadia56%
$43 → $43ReiteratesBuy → BuyGet Alert
02/21/2024Buy Now434.16%Needham
Ami Fadia56%
$43 → $43ReiteratesBuy → BuyGet Alert
02/21/2024Buy Now645.34%Canaccord Genuity
Bill Maughan19%
→ $60ReiteratesBuy → BuyGet Alert
02/21/2024Buy Now583.23%HC Wainwright & Co.
Swayampakula Ramakanth50%
$57 → $55MaintainsBuyGet Alert
12/20/2023Buy Now297.52%JMP Securities
Reni Benjamin47%
$44 → $32MaintainsMarket OutperformGet Alert
12/15/2023Buy Now434.16%Needham
Ami Fadia56%
$46 → $43MaintainsBuyGet Alert
11/08/2023Buy Now707.45%Cantor Fitzgerald
Li Watsek40%
→ $65ReiteratesOverweight → OverweightGet Alert
11/03/2023Buy Now396.89%Morgan Stanley
Jeffrey Hung50%
$42 → $40MaintainsEqual-WeightGet Alert
09/12/2023Buy Now309.94%B. Riley Securities
Kalpit Patel40%
→ $33UpgradeNeutral → BuyGet Alert
09/12/2023Buy Now707.45%Cantor Fitzgerald
Li Watsek40%
→ $65ReiteratesOverweight → OverweightGet Alert
09/12/2023Buy Now446.58%JMP Securities
Reni Benjamin47%
→ $44ReiteratesMarket Outperform → Market OutperformGet Alert
09/12/2023Buy Now471.43%Needham
Ami Fadia56%
→ $46ReiteratesBuy → BuyGet Alert
09/11/2023Buy Now309.94%B. Riley Securities
Kalpit Patel40%
$33 → $33UpgradeNeutral → BuyGet Alert
09/07/2023Buy Now707.45%Cantor Fitzgerald
Li Watsek40%
→ $65ReiteratesOverweight → OverweightGet Alert
08/04/2023Buy Now421.74%Morgan Stanley
Jeffrey Hung50%
$42 → $42ReiteratesEqual-Weight → Equal-WeightGet Alert
08/04/2023Buy Now446.58%JMP Securities
Reni Benjamin47%
$46 → $44MaintainsOutperformGet Alert
08/04/2023Buy Now608.07%HC Wainwright & Co.
Swayampakula Ramakanth50%
→ $57ReiteratesBuy → BuyGet Alert
08/04/2023Buy Now471.43%Needham
Ami Fadia56%
$48 → $46MaintainsBuyGet Alert
08/03/2023Buy Now521.12%EF Hutton
Tony Butler42%
→ $50Reiterates → BuyGet Alert
05/11/2023Buy Now471.43%JMP Securities
Reni Benjamin47%
$46 → $46ReiteratesMarket Outperform → Market OutperformGet Alert
05/08/2023Buy Now583.23%Oppenheimer
Jay Olson60%
→ $55Reiterates → OutperformGet Alert
05/05/2023Buy Now471.43%JMP Securities
Reni Benjamin47%
→ $46Reiterates → Market OutperformGet Alert
05/05/2023Buy Now608.07%HC Wainwright & Co.
Swayampakula Ramakanth50%
→ $57Reiterates → BuyGet Alert
05/05/2023Buy Now695.03%Needham
Ami Fadia56%
$67 → $64MaintainsBuyGet Alert
04/19/2023Buy Now583.23%EF Hutton
Tony Butler42%
→ $55Reiterates → BuyGet Alert
04/18/2023Buy Now471.43%JMP Securities
Reni Benjamin47%
→ $46Reiterates → Market OutperformGet Alert
03/01/2023Buy Now608.07%HC Wainwright & Co.
Swayampakula Ramakanth50%
→ $57Reiterates → BuyGet Alert
03/01/2023Buy Now732.3%Needham
Ami Fadia56%
$72 → $67MaintainsBuyGet Alert
02/28/2023Buy Now583.23%EF Hutton
Tony Butler42%
→ $55Reiterates → BuyGet Alert
02/27/2023Buy Now819.25%Cantor Fitzgerald
Li Watsek40%
→ $74Reiterates → OverweightGet Alert
02/15/2023Buy Now583.23%EF Hutton
Tony Butler42%
→ $55Reiterates → BuyGet Alert
02/15/2023Buy Now608.07%HC Wainwright & Co.
Swayampakula Ramakanth50%
→ $57Reiterates → BuyGet Alert
02/15/2023Buy Now794.41%Needham
Ami Fadia56%
→ $72Reiterates → BuyGet Alert
01/05/2023Buy Now583.23%EF Hutton
Tony Butler42%
→ $55Initiates → BuyGet Alert
11/09/2022Buy Now471.43%JMP Securities
Reni Benjamin47%
$70 → $46MaintainsMarket OutperformGet Alert
09/12/2022Buy Now459.01%Morgan Stanley
Jeffrey Hung50%
$60 → $45MaintainsEqual-WeightGet Alert
08/31/2022Buy NowCowen & Co.
Tara Bancroft57%
Initiates → OutperformGet Alert
08/22/2022Buy Now521.12%SVB Leerink
Jonathan Chang38%
$48 → $50MaintainsOutperformGet Alert
08/05/2022Buy Now496.27%SVB Leerink
Jonathan Chang38%
$69 → $48MaintainsOutperformGet Alert
08/05/2022Buy Now608.07%HC Wainwright & Co.
Swayampakula Ramakanth50%
$65 → $57MaintainsBuyGet Alert
07/28/2022Buy Now272.67%Barclays
Peter Lawson42%
→ $30Initiates → OverweightGet Alert
07/06/2022Buy Now645.34%Canaccord Genuity
William Maughan71%
→ $60Assumes → BuyGet Alert
05/23/2022Buy Now359.63%Piper Sandler
Edward Tenthoff50%
$76 → $37MaintainsOverweightGet Alert

FAQ

Q

What is the target price for Bicycle Therapeutics (BCYC) stock?

A

The latest price target for Bicycle Therapeutics (NASDAQ:BCYC) was reported by Morgan Stanley on May 6, 2025. The analyst firm set a price target for $17.00 expecting BCYC to rise to within 12 months (a possible 111.18% upside). 33 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Bicycle Therapeutics (BCYC)?

A

The latest analyst rating for Bicycle Therapeutics (NASDAQ:BCYC) was provided by Morgan Stanley, and Bicycle Therapeutics maintained their equal-weight rating.

Q

When was the last upgrade for Bicycle Therapeutics (BCYC)?

A

The last upgrade for Bicycle Therapeutics PLC happened on September 12, 2023 when B. Riley Securities raised their price target to $33. B. Riley Securities previously had a neutral for Bicycle Therapeutics PLC.

Q

When was the last downgrade for Bicycle Therapeutics (BCYC)?

A

The last downgrade for Bicycle Therapeutics PLC happened on August 7, 2024 when B. Riley Securities changed their price target from $33 to $28 for Bicycle Therapeutics PLC.

Q

When is the next analyst rating going to be posted or updated for Bicycle Therapeutics (BCYC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bicycle Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bicycle Therapeutics was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.

Q

Is the Analyst Rating Bicycle Therapeutics (BCYC) correct?

A

While ratings are subjective and will change, the latest Bicycle Therapeutics (BCYC) rating was a maintained with a price target of $15.00 to $17.00. The current price Bicycle Therapeutics (BCYC) is trading at is $8.05, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch